Company Overview - Awei Technology Co., Ltd. specializes in the research, development, production, sales, and service of medical clinical testing analysis instruments and in vitro diagnostic reagents, as well as medical consumables [1] - The company has developed a series of medical testing instruments based on original automatic microscopy technology, including automatic urine, feces, and reproductive tract secretion analyzers [1] Financial Performance - For Q1 2025, the company reported revenue of 53.30 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.32 million yuan, up 24.63% year-on-year [2] - The sales gross margin for the company stands at 55.59% [2] Market Position - As of May 12, Awei Technology's stock closed at 19.98 yuan, with a rolling price-to-earnings (PE) ratio of 56.40, marking a new low in 36 days [1] - The average PE ratio for the medical device industry is 49.84, with a median of 36.59, placing Awei Technology at the 90th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders for Awei Technology is 3,605, a decrease of 14 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

爱威科技股份有限公司是一家主营业务为医疗临床检验分析仪器及配套体外诊断试剂、医用耗材的研 发、生产、销售和服务一体化的高新技术企业。公司基于原创性医学显微镜自动镜检技术开发出全自动 尿液、粪便、生殖道分泌物等多系列医学检验仪器,并自主开发生产与检验仪器相配套的试剂及医用耗 材产品。公司的主要产品有尿液有形成分分析仪、尿液干化学分析仪、尿全项自动分析仪、全自动粪便 分析仪、全自动体液分析仪、生殖道分泌物分析仪、专用配套体外诊断试剂、医用耗材。公司获得 了"国家知识产权示范企业"、"国家知识产权优势企业"、"中国专利优秀奖(图像处理方法和装置)"等多 项荣誉奖项。 5月6日，爱威科技今日收盘19.48元，上涨3.78%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到54.99倍，创30天以来新低，总市值13.25亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均48.90倍，行业中值36.41倍，爱威科技排 名第89位。 截至2025年一季报，共有5家机构持仓爱威科技，其中其他3家、基金2家，合计持股数543.66万股，持 股市值0.98亿元。 来源：金融界 最新一期业绩显示，2025年 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology, which operates in the medical device industry [1][2] - As of April 28, Aiwei Technology's stock closed at 17.85 yuan, down 1.60%, with a rolling PE ratio of 52.83 times and a total market capitalization of 1.214 billion yuan [1] - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Aiwei Technology at the 89th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, Aiwei Technology reported an operating income of 53.2953 million yuan, representing a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, up 24.63% [2] - The company's sales gross margin stands at 55.59% [2] - Aiwei Technology specializes in the research, development, production, and sales of medical clinical testing analysis instruments and related in vitro diagnostic reagents, with a range of products including automated urine analyzers and fecal analysis instruments [1]

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.94倍，行业中值29.64倍，爱威科技排 名第95位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)95爱威科技52.0652.062.3911.96亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.2411.51亿9热景生物-60.65-60.653.33108.69亿10华大智造-52.74-52.743.96315.97 亿11中红医疗-48.32-32.870.7743.02亿 来源：金融界 截至2024年三季报，共有44家机构持仓爱威科 ...